A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.

Exclusion Criteria13

• Have any other form of amyloidosis other than AL amyloidosis
• Mayo Stage IIIb AL amyloidosis
• Oxygen saturation \< 95% on room air
• Systolic blood pressure \<100mmHg
• NYHA class III or IV
• Extensive GI involvement with evidence of active GI bleeding/risk of bleeding as determined by Investigator
• Prior therapies:
• CAR T cell therapy directed at any target
• Prior BCMA-targeting therapy
• Prior treatment with any FDA approved or investigational T cell engaging therapies (including T cell-directed bispecific or trispecific therapies) at any target within the last 6 months.
• Toxicity from previous anti-cancer or anti-PC-directed therapy did not resolve to baseline levels or to Grade 1 or less except for alopecia or peripheral neuropathy.
• Active plasma cell leukemia at the time of screening
• Symptomatic multiple myeloma (defined as clonal bone marrow plasma cells ≥10% plus at least one myeloma-defining event per IMWG 2014)